Transgenic Angiopoietin-Like (Angptl)4 Overexpression and Targeted Disruption of Angptl4 and Angptl3: Regulation of Triglyceride Metabolism
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Lipoprotein lipase (LPL) is a key regulator of triglyceride clearance. Its coordinated regulation during feeding and fasting is critical for maintaining lipid homeostasis and energy supply. Angiopoietin-like (Angptl)3 and Angptl4 are secreted proteins that have been demonstrated to regulate triglyceride metabolism by inhibiting LPL. We have taken a targeted genetic approach to generate Angptl4- and Angptl3-deficient mice as well as transgenic mice overexpressing human Angptl4 in the liver. The Angptl4 transgenic mice displayed elevated plasma triglycerides and reduced postheparin plasma (PHP) LPL activity. A purified recombinant Angptl4 protein inhibited mouse LPL and recombinant human LPL activity in vitro. In contrast to the transgenic mice, Angptl4-deficient mice displayed hypotriglyceridemia and increased PHP LPL activity, with greater effects in the fasted compared with the fed state. Angptl3-deficient mice also displayed hypotriglyceridemia with elevated PHP LPL activity, but these mice showed a greater effect in the fed state. Mice deficient in both Angptl proteins showed an additive effect on plasma triglycerides and did not survive past 2 months of age. Our results show that Angptl3 and Angptl4 function to regulate circulating triglyceride levels during different nutritional states and therefore play a role in lipid metabolism during feeding/fasting through differential inhibition of LPL.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ANGPTL3 inhibits the lipoprotein lipase, which results in increased blood lipid levels [143–145].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [143]
In the citing paper
“Evinacumab is a monoclonal antibody inhibiting angiopoietin-like 3 (ANGPTL3).”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [143]
In the citing paper
“In contrast to other pharmacological treatments, evinacumab’s MoA is therefore independent of the LDL-C receptor [143, 148], providing new options for more synergistic combination treatments.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [143]
In the citing paper
“Thus, Angptl4 knockout mice have reduced plasma triglycerides, whereas Angptl4 overexpressing mice have increased triglyceride levels [9,10].”
From Differential effects of angiopoietin-like 4 in brain and muscle on regulation of lipoprotein lipase activity (2015) · cites this paper as [9]
In the citing paper
“Conversely, ANGPTL4-deficient mice had lower than normal plasma triglycerides and higher postheparin-plasma LPL activity (16).”
From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [16]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Enzyme kinetics; behavior and analysis of rapid equilibrium and steady state enzyme systems
(1994) · International Journal of Biochemistry · doi:10.1016/0020-711x(94)90021-3 · Cited by 2,972
Lipoprotein lipase: structure, function, regulation, and role in disease
Mead, J., Irvine, S., & Ramji, D. (2002) · Journal of Molecular Medicine · doi:10.1007/s00109-002-0384-9 · Cited by 927
Merkel, M., Eckel, R. H., & Goldberg, I. J. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200015-jlr200 · Cited by 522
Kersten, S., Mandard, S., Tan, N. S., Escher, P., Metzger, D., Chambon, P., Gonzalez, F. J., Desvergne, B., & Wahli, W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004029200 · Cited by 489
Angptl3 regulates lipid metabolism in mice
Koishi, R., Ando, Y., Ono, M., Shimamura, M., Yasumo, H., Fujiwara, T., Horikoshi, H., & Furukawa, H. (2002) · Nature Genetics · doi:10.1038/ng814 · Cited by 379
Yoon, J. C., Chickering, T. W., Rosen, E. D., Dussault, B., Qin, Y., Soukas, A., Friedman, J. M., Holmes, W. E., & Spiegelman, B. M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.14.5343-5349.2000 · Cited by 356
Shimizugawa, T., Ono, M., Shimamura, M., Yoshida, K., Ando, Y., Koishi, R., Ueda, K., Inaba, T., Minekura, H., Kohama, T., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203215200 · Cited by 339
Yoshida, K., Shimizugawa, T., Ono, M., & Furukawa, H. (2002) · Journal of Lipid Research · doi:10.1194/jlr.c200010-jlr200 · Cited by 317
Kim, I., Kim, H.-G., Kim, H. W., Kim, H.-H., Park, S. K., Uhm, C.-S., Lee, Z. H., & Koh, G. Y. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3460603 · Cited by 284
Weinstock, P. H., Bisgaier, C. L., Aalto-Setälä, K., Radner, H., Ramakrishnan, R., Levak-Frank, S., Essenburg, A. D., Zechner, R., & Breslow, J. L. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118319 · Cited by 254
Cited by
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495
Lipoprotein lipase: from gene to obesity
Wang, H., & Eckel, R. H. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90920.2008 · Cited by 741
“Specifically, Angptl-3 and Angptl-4 inhibit LPL activity and are associated with hypertriglyceridemia (127; 136; 250).”
BackgroundEvinacumab for Homozygous Familial Hypercholesterolemia
Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Hovingh, G. K., Kastelein, J. J. P., Rubba, P., Ali, S., Banerjee, P., Chan, K.-C., Gipe, D. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004215 · Cited by 793
Feige, J. N., Gelman, L., Michalik, L., Desvergne, B., & Wahli, W. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2005.12.002 · Cited by 786
Exome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754
Physiological regulation of lipoprotein lipase
Kersten, S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.03.013 · Cited by 550
Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association
Bays, H. E., Toth, P. P., Kris-Etherton, P. M., Abate, N., Aronne, L. J., Brown, W. V., Gonzalez-Campoy, J. M., Jones, S. R., Kumar, R., La Forge, R., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.04.001 · Cited by 521
Romeo, S., Pennacchio, L. A., Fu, Y., Boerwinkle, E., Tybjaerg-Hansen, A., Hobbs, H. H., & Cohen, J. C. (2007) · Nature Genetics · doi:10.1038/ng1984 · Cited by 511
“Mice with a genetic deletion of ANGPTL4 have lower plasma triglyceride level”
BackgroundInactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510926 · Cited by 497
Plasma lipoproteins: genetic influences and clinical implications
Hegele, R. A. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2481 · Cited by 462
Atypical angiopoietin-like protein that regulates ANGPTL3
Quagliarini, F., Wang, Y., Kozlitina, J., Grishin, N. V., Hyde, R., Boerwinkle, E., Valenzuela, D. M., Murphy, A. J., Cohen, J. C., & Hobbs, H. H. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217552109 · Cited by 409
“Angptl3 mice have increased LPL activity (8, 13, 14), and recombinant ANGPTL3 inhibits LPL in vitro (6, 13, 15, 16), leading several investigators to propose that ANGPTL3 raises plasma TAG levels by inhibiting LPL activity (13, 14).”
BackgroundInfluentialMandard, S., Zandbergen, F., van Straten, E., Wahli, W., Kuipers, F., Müller, M., & Kersten, S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m506519200 · Cited by 433
Romeo, S., Yin, W., Kozlitina, J., Pennacchio, L. A., Boerwinkle, E., Hobbs, H. H., & Cohen, J. C. (2008) · Journal of Clinical Investigation · doi:10.1172/jci37118 · Cited by 58
“Both ANGPTL3 and ANGPTL4 inhibit LPL activity in vitro and in vivo (4–6), and mice lacking Angptl3 or Angptl4 have increased LPL activity and reduced levels of plasma TG (7, 8).”
BackgroundSukonina, V., Lookene, A., Olivecrona, T., & Olivecrona, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604026103 · Cited by 360
Dissecting adipose tissue lipolysis: molecular regulation and implications for metabolic disease
Nielsen, T. S., Jessen, N., Jørgensen, J. O. L., Møller, N., & Lund, S. (2014) · Journal of Molecular Endocrinology · doi:10.1530/jme-13-0277 · Cited by 380
“The fasting-induced circulating factor angiopoietin-like protein 4 (ANGPTL4) is a well-established negative regulator of lipid uptake in rodent adipocytes through inhibition of extracellular lipoprotein lipase activity (Koster et al .”
The Role of Angiopoietin-Like Proteins in Angiogenesis and Metabolism
Hato, T., Tabata, M., & Oike, Y. (2008) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2007.10.003 · Cited by 351
Zhang, R. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.07.038 · Cited by 311
Biochemistry and pathophysiology of intravascular and intracellular lipolysis
Young, S. G., & Zechner, R. (2013) · Genes & Development · doi:10.1101/gad.209296.112 · Cited by 348
“Missense mutations in the gene for ANGPTL4, a lipase inhibitor (Yoshida et al. 2002; Koster et al. 2005), result in lower plasma TG levels (Romeo et al. 2007, 2009; Yin et al. 2009).”
BackgroundProbiotics, prebiotics, synbiotics and insulin sensitivity
Kim, Y. A., Keogh, J. B., & Clifton, P. M. (2018) · Nutrition Research Reviews · doi:10.1017/s095442241700018x · Cited by 335
“In mice, overexpression of ANGPTL4 decreased clearance of TAG-rich lipoproteins and increased circulating TAG levels (141) .”
BackgroundProbiotics and Prebiotics: Present Status and Future Perspectives on Metabolic Disorders
Yoo, J., & Kim, S. (2016) · Nutrients · doi:10.3390/nu8030173 · Cited by 328
“Moreover, research has indicated that overexpression of ANGPTL4 in the liver leads to decreased activation of LPL and increased plasma triglyceride levels [118].”
BackgroundWang, Y., Quagliarini, F., Gusarova, V., Gromada, J., Valenzuela, D. M., Cohen, J. C., & Hobbs, H. H. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1315292110 · Cited by 317
“Similar findings were observed previously in Angptl3 (4, 7), Angptl4 (7), and Angptl8 mice”
BackgroundResultAlex, S., Lange, K., Amolo, T., Grinstead, J. S., Haakonsson, A. K., Szalowska, E., Koppen, A., Mudde, K., Haenen, D., Al-Lahham, S., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00858-12 · Cited by 296
Zhu, P., Tan, M. J., Huang, R.-L., Tan, C. K., Chong, H. C., Pal, M., Lam, C. R. I., Boukamp, P., Pan, J. Y., Tan, S. H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.018 · Cited by 283
Lichtenstein, L., Mattijssen, F., de Wit, N. J., Georgiadi, A., Hooiveld, G. J., van der Meer, R., He, Y., Qi, L., Köster, A., Tamsma, J. T., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.11.002 · Cited by 251
“Studies using different transgenic mouse models of Angptl4 overexpression or deletion show that Angptl4 potently raises plasma TG levels by suppressing LPL-mediated clearance of plasma TG-rich lipoproteins (Koster et al., 2005; Mandard et al., 2006; Xu et al., 2005).”
Self-citationGenetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease
Rosenson, R. S., Davidson, M. H., Hirsh, B. J., Kathiresan, S., & Gaudet, D. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.042 · Cited by 260
Angiopoietin-like 4: a decade of research
Zhu, P., Goh, Y. Y., Chin, H. F. A., Kersten, S., & Tan, N. S. (2012) · Bioscience Reports · doi:10.1042/bsr20110102 · Cited by 261
Hepatokines and metabolism: Deciphering communication from the liver
Jensen-Cody, S. O., & Potthoff, M. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101138 · Cited by 252
Galaup, A., Cazes, A., Le Jan, S., Philippe, J., Connault, E., Le Coz, E., Mekid, H., Mir, L. M., Opolon, P., Corvol, P., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609025103 · Cited by 252
Liu, D. J., & Leal, S. M. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001156 · Cited by 236
ANGPTL4 in Metabolic and Cardiovascular Disease
Aryal, B., Price, N. L., Suarez, Y., & Fernández-Hernando, C. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.05.010 · Cited by 234
“The decrease in LPL activity was more pronounced in mice after fasting [47, 48].”
BackgroundLipoprotein lipase and its regulators: an unfolding story
Wu, S. A., Kersten, S., & Qi, L. (2021) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.11.005 · Cited by 225
Genetic causes of high and low serum HDL-cholesterol
Weissglas-Volkov, D., & Pajukanta, P. (2010) · Journal of Lipid Research · doi:10.1194/jlr.r004739 · Cited by 224
The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking
Zhang, R. (2016) · Open Biology · doi:10.1098/rsob.150272 · Cited by 219
Angiopoietin-like 3 in lipoprotein metabolism
Kersten, S. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.119 · Cited by 220
Gusarova, V., Alexa, C. A., Wang, Y., Rafique, A., Kim, J. H., Buckler, D., Mintah, I. J., Shihanian, L. M., Cohen, J. C., Hobbs, H. H., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m054890 · Cited by 210
Kersten, S., Lichtenstein, L., Steenbergen, E., Mudde, K., Hendriks, H. F. J., Hesselink, M. K., Schrauwen, P., & Müller, M. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.182147 · Cited by 178
ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance
Haller, J. F., Mintah, I. J., Shihanian, L. M., Stevis, P., Buckler, D., Alexa-Braun, C. A., Kleiner, S., Banfi, S., Cohen, J. C., Hobbs, H. H., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m075689 · Cited by 199
Maternal and fetal lipid metabolism under normal and gestational diabetic conditions
Herrera, E., & Desoye, G. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2015-0025 · Cited by 202
“ANGPTL4 is secreted into serum from adipose tissue, liver, and placenta [192] and its overexpression in mice or treatment with it increase TAG levels as result of irreversible inhibition of LPL activity [193].”
BackgroundDUVAL, C., MULLER, M., & KERSTEN, S. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.05.003 · Cited by 199
Regulation of lipoprotein lipase by Angptl4
Dijk, W., & Kersten, S. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.12.005 · Cited by 198
Lichtenstein, L., Berbée, J. F. P., van Dijk, S. J., van Dijk, K. W., Bensadoun, A., Kema, I. P., Voshol, P. J., Müller, M., Rensen, P. C. N., & Kersten, S. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.151894 · Cited by 163
Regulation of lipid metabolism by angiopoietin-like proteins
Dijk, W., & Kersten, S. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000290 · Cited by 192
“The inhibitory effect of ANGPTL4 on LPL activity has been extensively documented in numerous in vivo and in vitro studies [5,12].”
BackgroundDesai, U., Lee, E.-C., Chung, K., Gao, C., Gay, J., Key, B., Hansen, G., Machajewski, D., Platt, K. A., Sands, A. T., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705041104 · Cited by 175
Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion
Wang, Y., Gusarova, V., Banfi, S., Gromada, J., Cohen, J. C., & Hobbs, H. H. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m054882 · Cited by 189
“The experiment was performed first in WT mice 4 h after refeeding, since ANGPTL3 appears to be most active in the fed state (39).”
Staiger, H., Haas, C., Machann, J., Werner, R., Weisser, M., Schick, F., Machicao, F., Stefan, N., Fritsche, A., & Häring, H.-U. (2009) · Diabetes · doi:10.2337/db07-1438 · Cited by 183
Regulation of triglyceride metabolism by Angiopoietin-like proteins
Mattijssen, F., & Kersten, S. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.010 · Cited by 180
Pathway Signature and Cellular Differentiation in Clear Cell Renal Cell Carcinoma
Tun, H. W., Marlow, L. A., von Roemeling, C. A., Cooper, S. J., Kreinest, P., Wu, K., Luxon, B. A., Sinha, M., Anastasiadis, P. Z., & Copland, J. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010696 · Cited by 178
“Angiopoietin-like 4 (ANGPTL4, NM_016109), which increases triglycerides by potent inhibition of lipoprotein lipase [17], was increased in ccRCC tumor tissue by 23-fold and may play a major role in lipid accumulation.”
BackgroundRobciuc, M. R., Maranghi, M., Lahikainen, A., Rader, D., Bensadoun, A., Öörni, K., Metso, J., Minicocci, I., Ciociola, E., Ceci, F., et al. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301397 · Cited by 163
ANGPTL8 promotes the ability of ANGPTL3 to bind and inhibit lipoprotein lipase
Chi, X., Britt, E. C., Shows, H. W., Hjelmaas, A. J., Shetty, S. K., Cushing, E. M., Li, W., Dou, A., Zhang, R., & Davies, B. S. J. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.014 · Cited by 174
“Based on our inhibition data, these concentrations of ANGPTL3 would have minimal impact on LPL activity, yet ANGPTL3-deficient mice clearly have reduced plasma triglyceride levels and increased LPL activity [10,11,14].”
BackgroundGealekman, O., Burkart, A., Chouinard, M., Nicoloro, S. M., Straubhaar, J., & Corvera, S. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90345.2008 · Cited by 174
“ANGPTL4 has also been studied extensively due to its unusual effect to directly inhibit lipoprotein lipase, an effect that leads to hypertriglyceridemia upon enforced overexpression of ANGPTL4 in animals (30, 54, 55), and to decreased levels of triglycerides in animals in which ANGPTL4 is knocked out or neutralized (1…”
BackgroundMinicocci, I., Montali, A., Robciuc, M. R., Quagliarini, F., Censi, V., Labbadia, G., Gabiati, C., Pigna, G., Sepe, M. L., Pannozzo, F., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1298 · Cited by 168
Recent advances in pharmacotherapy for hypertriglyceridemia
Sahebkar, A., Chew, G. T., & Watts, G. F. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2014.07.002 · Cited by 164
Fenzl, A., Itariu, B. K., Kosi, L., Fritzer-Szekeres, M., Kautzky-Willer, A., Stulnig, T. M., & Kiefer, F. W. (2014) · Diabetologia · doi:10.1007/s00125-014-3208-x · Cited by 165
Lee, E.-C., Desai, U., Gololobov, G., Hong, S., Feng, X., Yu, X.-C., Gay, J., Wilganowski, N., Gao, C., Du, L.-L., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807899200 · Cited by 151
The proprotein convertases are potential targets in the treatment of dyslipidemia
Seidah, N. G., & Prat, A. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0172-7 · Cited by 178
Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8
Sylvers-Davie, K. L., & Davies, B. S. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00195.2021 · Cited by 154
Peroxisome Proliferator Activated Receptors and Lipoprotein Metabolism
Kersten, S. (2008) · PPAR Research · doi:10.1155/2008/132960 · Cited by 149
“It can be speculated that upregulation of Angptl4 may explain the inhibitory effect of PPARα agonists on LPL activity in macrophages, adipose tissue, and cardiomyocytes [73–76].”
Role and mechanism of the action of angiopoietin-like protein ANGPTL4 in plasma lipid metabolism
Kersten, S. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100150 · Cited by 145
“Earlier studies indicated that the liver-specific overexpression of ANGPTL4 raises plasma TG levels and decreases postheparin plasma LPL activity but does not influence hepatic VLDL secretion (24, 41, 60).”
BackgroundAngiopoietin-like 4 Interacts with Matrix Proteins to Modulate Wound Healing*
Goh, Y. Y., Pal, M., Chong, H. C., Zhu, P., Tan, M. J., Punugu, L., Tan, C. K., Huang, R.-L., Sze, S. K., Tang, M. B. Y., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.108175 · Cited by 145
Gusarova, V., O’Dushlaine, C., Teslovich, T. M., Benotti, P. N., Mirshahi, T., Gottesman, O., Van Hout, C. V., Murray, M. F., Mahajan, A., Nielsen, J. B., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04611-z · Cited by 145
Sanderson, L. M., Degenhardt, T., Koppen, A., Kalkhoven, E., Desvergne, B., Müller, M., & Kersten, S. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00370-09 · Cited by 144
“Angptl4 expression in all tissues (30).”
Genetic Variation in ANGPTL4 Provides Insights into Protein Processing and Function
Yin, W., Romeo, S., Chang, S., Grishin, N. V., Hobbs, H. H., & Cohen, J. C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900553200 · Cited by 129
Shan, L., Yu, X.-C., Liu, Z., Hu, Y., Sturgis, L. T., Miranda, M. L., & Liu, Q. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808477200 · Cited by 130
Hepatic ANGPTL3 regulates adipose tissue energy homeostasis
Wang, Y., McNutt, M. C., Banfi, S., Levin, M. G., Holland, W. L., Gusarova, V., Gromada, J., Cohen, J. C., & Hobbs, H. H. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515374112 · Cited by 134
“Plasma TG and cholesterol levels were lower in knockout (KO) mice, as reported previously (20), whereas plasma levels of nonesterified free fatty acids (NEFAs) and ketone bodies did not differ systematically between the two strains under these conditions (Fig.”
BackgroundAbsence of ANGPTL4 in adipose tissue improves glucose tolerance and attenuates atherogenesis
Aryal, B., Singh, A. K., Zhang, X., Varela, L., Rotllan, N., Goedeke, L., Chaube, B., Camporez, J.-P., Vatner, D. F., Horvath, T. L., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.97918 · Cited by 127
“Overexpression of ANGPTL4 in mice significantly increases circulating TAG levels, in concert with a decrease in LPL activity in post-heparin plasma (PHP) and tissues (18).”
Georgiadi, A., Lichtenstein, L., Degenhardt, T., Boekschoten, M. V., van Bilsen, M., Desvergne, B., Müller, M., & Kersten, S. (2010) · Circulation Research · doi:10.1161/circresaha.110.217380 · Cited by 133
Fu, Z., Yao, F., Abou-Samra, A. B., & Zhang, R. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.12.025 · Cited by 123
“adenoviruses in mice increases serum triglycerides [8,9,11].”
Angiopoietin-Like 4 Interacts with Integrins β1 and β5 to Modulate Keratinocyte Migration
Goh, Y. Y., Pal, M., Chong, H. C., Zhu, P., Tan, M., Punugu, L., Lam, C. R. I., Yau, Y. H., Tan, C. K., Huang, R.-L., et al. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100129 · Cited by 135
“Pure-bred ANGPTL4 / and ANGPTL4 / mice on a C57Bl/6 background were used.(23) Animal experiments were approved by the University Institutional Animal Care and Use Committee (ARF-SBS/NIE-A-0093, 0078, and 004).”
MethodANGPTL4 mediates shuttling of lipid fuel to brown adipose tissue during sustained cold exposure
Dijk, W., Heine, M., Vergnes, L., Boon, M. R., Schaart, G., Hesselink, M. K., Reue, K., van Marken Lichtenbelt, W. D., Olivecrona, G., Rensen, P. C., et al. (2015) · eLife · doi:10.7554/elife.08428 · Cited by 114
Pisciotta, L., Favari, E., Magnolo, L., Simonelli, S., Adorni, M. P., Sallo, R., Fancello, T., Zavaroni, I., Ardigò, D., Bernini, F., et al. (2012) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.111.960674 · Cited by 120
Hypothalamic Angptl4/Fiaf Is a Novel Regulator of Food Intake and Body Weight
Kim, H.-K., Youn, B.-S., Shin, M.-S., Namkoong, C., Park, K. H., Baik, J. H., Kim, J. B., Park, J.-Y., Lee, K.-U., Kim, Y.-B., et al. (2010) · Diabetes · doi:10.2337/db10-0145 · Cited by 126
“Like Angptl3, Angptl4 is an important regulator of triglyceride metabolism (14).”
BackgroundUpdate on the molecular biology of dyslipidemias
Ramasamy, I. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.10.033 · Cited by 155
Liu, J., Afroza, H., Rader, D. J., & Jin, W. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.144279 · Cited by 118
Regulation of lipid metabolism via angiopoietin-like proteins
Kersten, S. (2005) · Biochemical Society Transactions · doi:10.1042/bst0331059 · Cited by 123
Sonnenburg, W. K., Yu, D., Lee, E.-C., Xiong, W., Gololobov, G., Key, B., Gay, J., Wilganowski, N., Hu, Y., Zhao, S., et al. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m900145-jlr200 · Cited by 115
Mysling, S., Kristensen, K. K., Larsson, M., Kovrov, O., Bensadouen, A., Jørgensen, T. J., Olivecrona, G., Young, S. G., & Ploug, M. (2016) · eLife · doi:10.7554/elife.20958 · Cited by 77
“DOI: 10.7554/eLife.20958.001”
InfluentialOn the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity
Kovrov, O., Kristensen, K. K., Larsson, E., Ploug, M., & Olivecrona, G. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m088807 · Cited by 116
Angiopoietin-like 4 promotes intracellular degradation of lipoprotein lipase in adipocytes
Dijk, W., Beigneux, A. P., Larsson, M., Bensadoun, A., Young, S. G., & Kersten, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m067363 · Cited by 103
“CHO pgsA-745 cells were electroporated with an expression vector for Flag-tagged human ANGPTL4 (either the full-length protein hANGPTL4[1–406] or the amino-terminal domain of hANGPTL4 [1–160]) or a vector for V5tagged human LPL (or empty vector).”
BackgroundMethodYau, M.-H., Wang, Y., Lam, K. S. L., Zhang, J., Wu, D., & Xu, A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809802200 · Cited by 109
Gray, N. E., Lam, L. N., Yang, K., Zhou, A. Y., Koliwad, S., & Wang, J.-C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.294124 · Cited by 116
“For example, transgenicmice overexpressing Angptl4 in the WAT have increased levels of plasma TG and FFAs (4, 5), whereas the opposite is true ofmice lackingAngptl4 (Angptl4 / ) (6).”
BackgroundInfluentialSingh, A. K., Chaube, B., Zhang, X., Sun, J., Citrin, K. M., Canfrán-Duque, A., Aryal, B., Rotllan, N., Varela, L., Lee, R. G., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci140989 · Cited by 115
“The role of ANGPTL4 in mouse body weight regulation under both physiological and pathophysiological conditions has been controversial (13, 21, 28, 32).”
BackgroundEmerging roles of Lipasin as a critical lipid regulator
Zhang, R., & Abou‐Samra, A. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.01.129 · Cited by 119
Singh, A. K., Aryal, B., Chaube, B., Rotllan, N., Varela, L., Horvath, T. L., Suárez, Y., & Fernández-Hernando, C. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.03.011 · Cited by 110
Gene expression profile of the bone microenvironment in human fragility fracture bone
Hopwood, B., Tsykin, A., Findlay, D. M., & Fazzalari, N. L. (2008) · Bone · doi:10.1016/j.bone.2008.08.120 · Cited by 126
“[90]”
Aryal, B., Rotllan, N., Araldi, E., Ramírez, C. M., He, S., Chousterman, B. G., Fenn, A. M., Wanschel, A., Madrigal-Matute, J., Warrier, N., et al. (2016) · Nature Communications · doi:10.1038/ncomms12313 · Cited by 93
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
GPIHBP1, an endothelial cell transporter for lipoprotein lipase
Young, S. G., Davies, B. S. J., Voss, C. V., Gin, P., Weinstein, M. M., Tontonoz, P., Reue, K., Bensadoun, A., Fong, L. G., & Beigneux, A. P. (2011) · Journal of Lipid Research · doi:10.1194/jlr.r018689 · Cited by 108
Overexpression of Angiopoietin-Like Protein 4 Protects Against Atherosclerosis Development
Georgiadi, A., Wang, Y., Stienstra, R., Tjeerdema, N., Janssen, A., Stalenhoef, A., van der Vliet, J. A., de Roos, A., Tamsma, J. T., Smit, J. W. A., et al. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301698 · Cited by 86
“E3L mice is consistent with the relative minor effect of Angptl4 overexpression on plasma triglyceride and cholesterol levels in fed mice, as opposed to fasted mice.(10,12) Interestingly, the reduction in hypertriglyceridemia in Angptl4Tg.”
BackgroundJustice, A. E., Karaderi, T., Highland, H. M., Young, K. L., Graff, M., Lu, Y., Turcot, V., Auer, P. L., Fine, R. S., Guo, X., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0334-2 · Cited by 100
Janssen, A. W. F., Katiraei, S., Bartosinska, B., Eberhard, D., Willems van Dijk, K., & Kersten, S. (2018) · Diabetologia · doi:10.1007/s00125-018-4583-5 · Cited by 96
Zheng, J., Huynh, H., Umikawa, M., Silvany, R., & Zhang, C. C. (2011) · Blood · doi:10.1182/blood-2010-06-291716 · Cited by 96
Voshol, P. J., Rensen, P. C. N., van Dijk, K. W., Romijn, J. A., & Havekes, L. M. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2008.12.015 · Cited by 111
“efficiency on adipose tissue development The general concept that LPL activity positively correlates with obesity suggests that modulators of LPL activity such as activators (e.g. apoCII [28], apoE [29], apoAV [30]) and inhibitors (e.g. apoCI [31], apoCIII [32], Angptl4 [33]) as well as modulators of LPL expression (e…”
MethodInfluentialTalmud, P. J., Smart, M., Presswood, E., Cooper, J. A., Nicaud, V., Drenos, F., Palmen, J., Marmot, M. G., Boekholdt, S. M., Wareham, N. J., et al. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.176917 · Cited by 94
Abu‐Farha, M., Ghosh, A., Al‐Khairi, I., Madiraju, S. R. M., Abubaker, J. A., & Prentki, M. (2020) · Progress in Lipid Research · doi:10.1016/j.plipres.2020.101067 · Cited by 97
Zhang, R., & Zhang, K. (2022) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101140 · Cited by 90
Targeted deletion of fibrinogen like protein 1 reveals a novel role in energy substrate utilization
Demchev, V., Malana, G., Vangala, D., Stoll, J., Desai, A., Kang, H. W., Li, Y., Nayeb-Hashemi, H., Niepel, M., Cohen, D. E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058084 · Cited by 89
“These data are in keeping with findings in mice with targeted disruption of Angptl3 and Angptl4 where in the fasted state triglyceride levels were unchanged but cholesterol levels were decreased [11].”
BackgroundResultInfluentialThe Importance of Lipoprotein Lipase Regulation in Atherosclerosis
Kumari, A., Kristensen, K. K., Ploug, M., & Winther, A.-M. L. (2021) · Biomedicines · doi:10.3390/biomedicines9070782 · Cited by 115
“Human ANGPTL4 is a 50 kDa glycoprotein highly expressed in WAT, but also in other tissues/cell types such as liver and in macrophages [143].”
BackgroundInfluentialAngiopoietin-like Protein 4 Inhibition of Lipoprotein Lipase
Lafferty, M. J., Bradford, K. C., Erie, D. A., & Neher, S. B. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.497602 · Cited by 88
“Mice lacking ANGPTL4 show increased LPL activity and decreased plasma triglycerides, whereas mice overexpressing ANGPTL4 display elevated plasma triglycerides and reduced LPL activity (16).”
BackgroundAngiopoietin-like 4 directs uptake of dietary fat away from adipose during fasting
Cushing, E. M., Chi, X., Sylvers, K. L., Shetty, S. K., Potthoff, M. J., & Davies, B. S. J. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.06.007 · Cited by 88
“Triglyceride clearance is increased in the adipose depots of Angptl4 / mice Given that ANGPTL4 inhibits LPL activity [6,7,9], the reduced plasma triglycerides in Angptl4 / mice are likely the result of increased LPL-”
BackgroundInfluentialAngptl4 serves as an endogenous inhibitor of intestinal lipid digestion
Mattijssen, F., Alex, S., Swarts, H. J., Groen, A. K., van Schothorst, E. M., & Kersten, S. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.11.004 · Cited by 88
Metadata
- Authors
- Köster, A., Chao, Y. B., Mosior, M., Ford, A., Gonzalez-DeWhitt, P. A., Hale, J. E., Li, D., Qiu, Y., Fraser, C. C., Yang, D. D., Heuer, J. G., Jaskunas, S. R., & Eacho, P.
- Affiliations
- Eli Lilly (United States) (US)
- Takeda Oncology (United States) (US)
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2005-11-01
- Volume
- 146
- Issue
- 11
- Pages
- 4943-4950
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2117617326
- Semantic Scholar
- 6382419c744ba19464b065395484df9cb3cf3eaf
- Cited by
- 427
- References
- 36
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 14 · 2023: 15 · 2022: 11 · 2021: 41 · 2020: 26 · 2019: 20 · 2018: 33 · 2017: 21 · 2016: 23 · 2015: 26 · 2014: 27 · 2013: 29 · 2012: 22
- FWCI
- 9.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Surgery › Lymphatic Disorders and Treatments
- Keywords
- ANGPTL4, ANGPTL3, lipoprotein lipase, triglyceride metabolism, hypotriglyceridemia, plasma triglycerides, lipoprotein lipase inhibition, fasting and feeding, lipid homeostasis, knockout mice, transgenic mice
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 4, Angiopoietin-Like Protein 3, Animals, Fasting, Heparin, Humans, Hyperlipidemias, Lipoprotein Lipase, Mice, Transgenic, Recombinant Proteins, Triglycerides, Survival Analysis, Mice, Knockout, Postprandial Period, Intercellular Signaling Peptides and Proteins, Angiopoietins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.